{"filings":[{"id":96350,"accession_number":"0001213900-26-054019","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Allarity Therapeutics CEO to present at Precision Medicine Forum Europe 2026","event_type":"other_material","confidence":"high","bullets":["CEO Thomas Jensen will speak on May 11, 2026, in Stockholm, Sweden at Precision Medicine Forum Europe 2026.","Presentation will cover stenoparib (2X-121), a dual PARP and WNT pathway inhibitor, and the Stenoparib DRP biomarker.","Allarity is a Phase 2 clinical-stage company developing stenoparib for cancer; no new clinical data or financial results announced.","A corporate presentation furnished as Exhibit 99.1 will be used in investor meetings beginning May 11, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96349,"accession_number":"0001213900-26-052542","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity Therapeutics updates stenoparib manufacturing on track for Q3 2026","event_type":"other_material","confidence":"high","bullets":["API manufacturing campaign on track for completion no later than Q3 2026 at GMP-compliant CDMO.","All manufacturing payments completed; no additional cash outlays anticipated.","Supports potential pivotal trial in advanced ovarian cancer following FDA Fast Track designation.","Ongoing Phase 2 trial in advanced ovarian cancer continues enrolling under amended protocol.","Phase 2 trial of stenoparib + temozolomide for relapsed SCLC recruiting across multiple VA sites."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96348,"accession_number":"0001213900-26-048277","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity Therapeutics receives USPTO Notice of Allowance for stenoparib DRP companion diagnostic patent","event_type":"regulatory","confidence":"high","bullets":["Notice of Allowance covers multiple claims for methods predicting clinical benefit and patient selection via gene expression.","Patent expected to be granted within three months; would provide exclusivity at least into 2039 for stenoparib with DRP test.","Allarity previously secured European and Australian patents for Stenoparib DRP; holds 18 granted patents for other drug-specific DRPs.","Patent applications for Stenoparib DRP remain pending in Canada, Japan, China, and India."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96347,"accession_number":"0001213900-26-046411","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity Therapeutics presents AACR posters on stenoparib for colorectal cancer and ovarian cancer survival","event_type":"other_material","confidence":"high","bullets":["Poster 2: stenoparib blocks WNT/β-catenin signaling and inhibits growth of colorectal cancer cell lines at clinically relevant concentrations.","Poster 1: Highest stenoparib DRP® scores are associated with enhanced overall survival in phase 2 ovarian cancer trial (NCT03878849).","CEO Thomas Jensen highlights stenoparib potential in colorectal cancer, a large area of unmet need in oncology.","DRP® companion diagnostic platform may identify patients most likely to achieve extended survival with stenoparib."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96346,"accession_number":"0001213900-26-038061","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allarity Therapeutics FY2025 net loss $11.2M, cash $14.7M, stenoparib Fast Track","event_type":"earnings","confidence":"high","bullets":["Net loss improved to $11.2M ($0.78/shr) from $25.1M ($15.65/shr) in 2024; first revenue of $320k.","Year-end cash $14.7M; extended runway with $20M non-convertible debt financing closed March 2026.","Stenoparib received FDA Fast Track for advanced ovarian cancer; new Phase 2 protocol implemented.","VA-funded Phase 2 combo trial (stenoparib+temozolomide) in SCLC opened at 11 VA sites; first patients dosed early 2026.","Jeff Ervin appointed CFO in July 2025 as part of leadership strengthening; DRP platform licensing initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110173,"accession_number":"0001213900-26-024952","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity closes $20M non-convertible debt with Streeterville; extends cash runway to mid-2028","event_type":"debt","confidence":"high","bullets":["Closed $20M non-convertible debt financing with Streeterville Capital via two promissory notes: $10.93M and $10M.","Net proceeds extend cash runway into summer 2028; funds Phase 2 ovarian cancer trial and FDA preparation.","Proceeds also support pivotal trial prep, companion diagnostic strategy, and potential expansion into other WNT-driven tumors.","Stenoparib has shown durable clinical benefit; some patients on therapy >30 months in Phase 2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110172,"accession_number":"0001213900-26-024339","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Allarity Therapeutics obtains $20M debt financing from Streeterville Capital with $20.93M notes","event_type":"debt","confidence":"high","bullets":["Issued $10.93M A-1 Note (9% interest) and $10M secured B Note (5% interest) for $20M purchase price.","$900K OID and $30K expense included; maturity 18 months from March 2, 2026.","B Note secured by $10M deposit account and pledge of ALLR Holdings LLC; guaranteed by three subsidiaries.","Covenants restrict additional debt, variable-rate issuances, and asset encumbrances without lender consent.","Investor can redeem up to $250K/month starting 6 months after closing; trigger events allow 10%/5% balance increases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110171,"accession_number":"0001213900-26-018161","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity Therapeutics doses first patients in VA-funded Phase 2 trial of stenoparib + temozolomide for relapsed SCLC","event_type":"other_material","confidence":"high","bullets":["First patients dosed with stenoparib and temozolomide in Phase 2 trial for relapsed small cell lung cancer (SCLC).","Trial fully funded by U.S. Department of Veterans Affairs, enrolling at 11 VA medical centers nationwide.","Stenoparib is a dual PARP and WNT pathway inhibitor; prior PARP inhibitors limited by hematologic toxicity.","CEO cites fast enrollment and high unmet need; ~60-70% of SCLC patients present with extensive-stage disease.","Stenoparib crosses blood-brain barrier, relevant for SCLC brain metastases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110170,"accession_number":"0001213900-26-011826","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity opens Phase 2 trial of stenoparib + temozolomide in relapsed SCLC","event_type":"other_material","confidence":"high","bullets":["Enrollment open at 11 VA sites for NCT06681220; trial fully funded by U.S. Department of Veterans Affairs.","Phase 2 evaluates stenoparib (dual PARP/WNT inhibitor) plus temozolomide in recurrent small cell lung cancer.","Study uses a blood-based biomarker to select patients most likely to benefit from the combination.","Stenoparib's favorable safety profile is cited as key rationale for combination with temozolomide.","Stenoparib crosses the blood-brain barrier, offering potential for brain metastases common in advanced SCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110169,"accession_number":"0001213900-26-009157","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Allarity Therapeutics enters $6M equity line of credit with Tumim Stone Capital","event_type":"other_material","confidence":"high","bullets":["Company may sell up to $6M of common stock at 95-97% of VWAP discount.","Commitment fee of $45,000 paid to investor upon execution.","Shares subject to Exchange Cap (19.99% of outstanding) unless stockholder waiver obtained.","Company must seek stockholder approval at next annual meeting to waive Exchange Cap.","Investor cannot own more than 4.99% (or 9.99% at its election) of outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126731,"accession_number":"0001213900-25-124935","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Allarity Therapeutics closes additional $250K private placement, issuing 255,103 shares at $0.98/share","event_type":"other_material","confidence":"high","bullets":["Additional Closing on Dec 23, 2025; 255,103 shares at $0.98/share for gross proceeds of ~$250,000.","Proceeds from the additional issuance will be used for general corporate purposes and working capital.","Shares were issued in a private placement under Section 4(a)(2) exemption, with restrictive legends."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126730,"accession_number":"0001213900-25-118989","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Allarity Therapeutics CFO Jeffrey Ervin moves to full-time; gets $367.7K salary, $160K RSUs","event_type":"leadership","confidence":"high","bullets":["CFO Jeffrey S. Ervin transitioned from part-time to full-time effective December 3, 2025 under new employment agreement.","Annual base salary set at $367,700; eligible for annual bonus up to 30% of base salary.","Granted restricted stock units valued at $160,000, vesting in equal installments over three years.","Severance of six months base salary if terminated without cause, for good reason, or in connection with change of control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143520,"accession_number":"0001213900-25-090872","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-09-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity Therapeutics: Phase 2 stenoparib shows median overall survival >25 months for platinum-resistant ovarian cancer","event_type":"other_material","confidence":"high","bullets":["Median overall survival (mOS) now exceeds 25 months, not yet formally reached, in ongoing Phase 2 trial.","Two patients remain on therapy >24 months; one with BRCA wild-type shows benefit, typically precluded by PARP inhibitors.","Data presented at AACR 2025 Ovarian Cancer Conference; FDA draft guidance supports OS as endpoint for approval.","Stenoparib shows less myelotoxicity vs earlier PARP inhibitors, relevant after 2022 market withdrawal of some PARP inhibitors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143519,"accession_number":"0001213900-25-090197","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Allarity Therapeutics raises ~$2.5M in private placement, with option for additional $7.5M","event_type":"other_material","confidence":"high","bullets":["Sold 1,562,500 shares at $1.60/sh and/or pre-funded warrants at $1.5999 for gross proceeds ~$2.5M.","Initial closing scheduled for Sept 23, 2025, subject to customary closing conditions.","Investor has 90-day option to purchase additional shares/warrants for up to $7.5M at then-current minimum price.","Shares and warrants issued in private placement under Section 4(a)(2); registration rights agreement filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143518,"accession_number":"0001213900-25-089680","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity CEO to present at Biomarkers & Precision Medicine 2025 in London on Oct 1","event_type":"other_material","confidence":"high","bullets":["CEO Thomas Jensen invited to present at Oxford Global conference on October 1, 2025.","Presentation title: 'A Gene Expression Based Biomarker For Predicting Response To Treatment With Stenoparib'.","Jensen will also be interviewed by Oxford Global's editorial team for their online portal.","Jensen available for one-on-one meetings during the conference to discuss business development.","Allarity is a Phase 2 clinical-stage company developing dual PARP/WNT inhibitor stenoparib."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143517,"accession_number":"0001213900-25-080923","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity receives FDA Fast Track for stenoparib in advanced ovarian cancer","event_type":"regulatory","confidence":"high","bullets":["FDA granted Fast Track designation to stenoparib for advanced ovarian cancer on August 26, 2025.","Fast Track enables expedited development, potential accelerated/priority review and rolling review.","Company began Phase 2 enrollment in June 2025; several patients already dosed.","Prior Phase 2 data showed durable clinical benefit including patients on treatment >22 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143516,"accession_number":"0001213900-25-064456","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity Therapeutics announces DRP licensing and lab services deal with EU biotech","event_type":"other_material","confidence":"high","bullets":["Non-exclusive global license to selected DRP algorithms in breast cancer granted to an undisclosed EU-based biotech company.","Allarity will provide advanced transcriptome analysis services from its Denmark lab; purchase commitments secured for next year.","Company states the agreement is not expected to have a significant impact on its financial outlook.","CEO Thomas Jensen says deal validates DRP platform and offsets internal operating costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143515,"accession_number":"0001213900-25-061639","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Allarity Therapeutics CFO resigns; appoints Jeffrey Ervin as part-time CFO effective July 1, 2025","event_type":"leadership","confidence":"high","bullets":["CFO Alexander Epshinsky resigned June 30, 2025; not due to any disagreement with the company.","Jeffrey S. Ervin appointed part-time CFO on July 1, 2025; annual base salary of $175,000.","Ervin previously served as fractional co-CFO of DDC Enterprise (NYSE: DDC) and chairman/CEO of IMAC Holdings (Nasdaq: BACK).","Ervin also serves as independent director of Cingulate, Inc. (Nasdaq: CING); holds MBA from Vanderbilt.","Severance: 6 months' base salary if terminated after Change-of-Control, subject to signed release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143514,"accession_number":"0001213900-25-060366","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity Therapeutics receives Australian patent acceptance for stenoparib DRP companion diagnostic","event_type":"regulatory","confidence":"high","bullets":["IP Australia accepted patent application covering 40 claims for DRP companion diagnostic specific to stenoparib.","Patent to be advertised June 26, 2025; three-month opposition period; grant expected within 20 working days if unopposed.","Company holds 18 granted drug-specific DRP patents, including 8 in US; European patent for stenoparib DRP previously secured.","Applications pending in US, Canada, Japan, China, and India."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161704,"accession_number":"0001437749-25-021482","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity dosed second patient in new Phase 2 stenoparib trial for advanced ovarian cancer","event_type":"other_material","confidence":"high","bullets":["Second patient dosed in new Phase 2 trial of stenoparib for advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer.","CEO Thomas Jensen cited strong investigator engagement and rapid enrollment pace.","Trial builds on prior Phase 2 data showing durable benefit and favorable tolerability with twice-daily dosing.","Stenoparib is a dual PARP and WNT pathway inhibitor; trial also advances DRP companion diagnostic.","Current platinum-resistant patients have limited treatment options; stenoparib aims to offer a better-tolerated alternative."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161703,"accession_number":"0001437749-25-020652","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Allarity shareholders reject equity plan increase and officer exculpation","event_type":"other_material","confidence":"high","bullets":["Thomas H. Jensen re-elected as Class III director with 1,673,698 for, 265,465 withheld.","Ratification of Wolf & Company as auditor passed with 6,706,148 votes for.","Proposal to increase 2021 Plan shares from 717,941 to 3,415,068 failed (928,978 for vs 932,866 against).","Amendment to limit officer liability (Officer Exculpation) also did not pass (1,359,331 for vs 563,585 against).","Adjournment proposal approved 4,976,159 for, 1,924,694 against; quorum was 41% of outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161702,"accession_number":"0001437749-25-020081","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Allarity Therapeutics appoints Jesper Høiland to board, replacing Joseph Vazzano","event_type":"leadership","confidence":"high","bullets":["Joseph Vazzano resigned as director effective June 30, 2025.","Jesper Høiland appointed director effective June 30, 2025; term expires at 2026 annual meeting.","Høiland joins Audit, Compensation, and Nominating & Governance Committees.","Høiland receives $50,000 annual retainer plus committee fees ($7,500/$5,000/$4,000).","Høiland had served as strategic consultant since Oct 2024; background includes Novo Nordisk and Radius Health."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161701,"accession_number":"0001437749-25-019471","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity Therapeutics partners with Indiana Biosciences Research Institute to study stenoparib's dual mechanism","event_type":"other_material","confidence":"medium","bullets":["Collaboration aims to clarify contributions of PARP inhibition and WNT pathway modulation to stenoparib's anticancer effects.","Stenoparib is a dual PARP1/2 and tankyrase1/2 inhibitor currently in Phase 2 trial for advanced ovarian cancer.","Research may support future marketing approval and potential expansion into colorectal cancer and SCLC combination trial.","No financial terms of the collaboration were disclosed in the press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161700,"accession_number":"0001437749-25-019219","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity enrolls first patient in Phase 2 stenoparib trial for advanced ovarian cancer","event_type":"other_material","confidence":"high","bullets":["First patient dosed in new Phase 2 protocol for platinum-resistant or platinum-ineligible advanced ovarian cancer.","Trial includes DRP companion diagnostic to enrich for stenoparib responders.","Two patients remain on prior Phase 2 study on twice-daily dosing, deriving benefit beyond 20 months.","Additional dosing level added aligning with FDA Project Optimus to inform pivotal trial design.","Company expects significant clinical data by late summer 2026; pursuing accelerated regulatory pathways."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}